CXCR2 and cancer: The past decade has witnessed the generation and development of antagonists to CXCR1 and CXCR2, and multiple clinical trials are underway investigating the therapeutic potential of targeting this signaling axis in inflammatory disorders and cancers (NCT03161431, NCT04245397, NCT03400332) [19–22].